Double Marker ( Dual Marker) Fmf

This prenatal screening combines measurement of two substances in maternal blood—usually pregnancy-associated plasma protein-A and free beta hCG—along with maternal age and ultrasound findings to assess the risk of chromosomal abnormalities in the developing fetus. Being FMF approved ensures adherence to international standards for accuracy and reliability. The test is non-invasive and poses no risk to the mother or baby.

Why consider DOUBLE MARKER (FMF) BY TRF METHOD,SERUM test?

The main purpose is to estimate the likelihood of conditions such as Down syndrome (trisomy 21) and Edwards syndrome (trisomy 18). While not diagnostic, it provides important early information that can guide further testing. A low-risk result can provide reassurance, while a high-risk finding helps doctors decide whether additional investigations like chorionic villus sampling or amniocentesis are necessary. Early risk assessment supports informed decision-making during pregnancy.

Who should get DOUBLE MARKER (FMF) BY TRF METHOD,SERUM test done?

Healthcare providers may recommend it for:

• Pregnant women in the first trimester (usually between 9- 13.6 weeks)

• Expectant mothers over the age of 35, who have a higher baseline risk

• Women with a family history of chromosomal abnormalities

• Couples seeking reassurance about fetal health early in pregnancy

More information about DOUBLE MARKER (FMF) BY TRF METHOD,SERUM test

This is a screening, not a diagnostic tool. Results are given as probabilities, combining blood test findings with ultrasound measurements such as nuchal translucency. A high-risk outcome does not confirm an abnormality but indicates the need for confirmatory testing. A normal or low-risk result greatly reduces the likelihood of chromosomal issues but does not completely rule them out. Counseling is recommended both before and after the test to ensure clear understanding of its scope and limitations.